| Cat.No. | Name | Information |
|---|---|---|
| M2206 | TH-302 (Evofosfamide) | TH-302 is a highly potent and selective hypoxia-activated procompound targeting hypoxic regions of solid tumors with IC50 of 19 nM. |
| M6098 | Baicalein | Baicalein is a CYP2C9 and prolyl endopeptidase inhibitor, IC50 value of 3.12 mM. |
| M9325 | EGTA | EGTA is a specific calcium chelator with a Kd of 60.5 nM at physiological pH (7.4) and a high specificity for Ca2+ than for Mg2+.EGTA significantly inhibits the substrate adhesion capacity of inflammatory macrophages. |
| M9330 | Brij-35 | Brij-35 (Polidocanol) is a high HLB, ethoxylated, nonionic ether of lauryl alcohol with broad pH stability. |
| M6154 | 2-PMPA tetrasodium | 2-PMPA (PMPA tetrasodium salt) is a potent and selective inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 300 pM. |
| M2250 | Pamidronate disodium | Pamidronate disodium is a nitrogen containing bisphosphonate, used to the research of preventing osteoporosis. |
| M9916 | DPPH | DPPH (2,2-Diphenyl-1-picrylhydrazyl) is a stable free radical that measures the free radical scavenging activity of antioxidants. |
| M9194 | Insulin (human) | Insulin (human) is a polypeptide hormone that regulates the level of sugar (glucose) in the blood and is produced by beta cells of islets. |
| M3409 | Formestane | Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM. |
| M9665 | N-(2-amino-2-oxoethyl)acrylamide | N-(2-Amino-2-oxoethyl)acrylamide |
| M21173 | Tanimilast | The M3 antagonist/PDE4 inhibitor dual pharmacology molecule 92a compound is an inhaled compound for lung disease.Tanimilast (CHF-6001) is a novel, potent, selective phosphodiesterase 4 inhibitor (IC50=0.026±0.006 nM) with potent anti-inflammatory activity suitable for topical lung administration. |
| M21170 | LY3202626 | LY3202626, a beta-site APP cleavage enzyme (BACE) inhibitor, is an orally administered, low-dose CNS permeant molecule. |
| M21169 | PF-60873600 | The CDK2/4/6 inhibitor PF-60873600 has oral bioactivity with low Ki values of 0.09 nM, 1.3 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. |
| M21164 | Acetyl tetrapeptide-5 | Acetyl tetrapeptide-5 inhibits glycosylation and ACE-1 activity. Acetyl tetrapeptide-5 reduces ocular edema and relieves vascular pressure by improving vascularity and strengthening the eye skin. acetyl tetrapeptide-5 can be used in antioxidant, anti-aging skin care studies. Sequence: Ac-Beta-Ala-His-Ser-His-OH. |
| M21163 | Decapeptide-12 | Decapeptide-12, a small oligopeptide, is a tyrosinase inhibitor that interacts with the C-terminal residue of tyrosinase (Kd: 61.1 μM). decapeptide-12 is a competitive inhibitor of mushroom tyrosinase (IC50: 40 µM ). Sequence: YRSRKYSSWY. |
| M21155 | NRX-252262 | NRX-252262 is a potent enhancer of the interaction of β-catenin with the homologous E3 ligase SCFβ-TrCP and promotes the degradation of β-catenin with an EC50 value of 3.8 nM. |
| M21154 | NRX-252114 | NRX-25211 is a potent enhancer of the interaction of β-catenin with the homologous E3 ligase SCFβ-TrCP, enhancing the binding of pSer33/S37A β-catenin to β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-25211 was able to promote the degradation of mutant β catenin degradation. |
| M21144 | JNJ-61803534 | JNJ-61803534 is an orally active RORgt inhibitor, JNJ-61803534 is an oral clinical candidate that is well tolerated in humans up to 200 mg and has shown PD. |
| M21124 | CVN424 | CVN424 is an orally active and selective GPR6 inverse agonist with a Ki of 9.4 nM and an EC50 of 38 nM. CVN424 can cross the blood-brain barrier and has potential for use in Parkinson's disease research. |
| M21123 | S62798 | Thrombin-activatable fibrinolytic inhibitor (TAFIa) inhibitor (S62798) is a fibrinolytic (clot-degrading) agent with an IC50 value of 6 mM. |
| M21122 | NITD-688 | The pan-serotype dengue virus (DENV) NS4B protein inhibitor NITD-688 is a preclinical candidate compound with strong in vitro activity against all four serotypes of dengue virus and excellent oral efficacy. |
| M21120 | SJF-0628 | SJF-0628 is a VHL-based xenofunctional degrader with in vivo activity in xenograft models (50 mg/kg BID IP). |
| M21100 | WX-081 | WX-081, an anti-tuberculosis agent (anti-tuberculosis), has excellent anti-mycobacterial activity against M. tuberculosis H37Rv. It is an oral mycobacterial ATP synthase inhibitor under development for the study of tuberculosis (TB). |
| M21096 | TXA6101 | TXA6101 is a filamentous temperature-sensitive mutant Z (FtsZ) protein inhibitor. TXA6101 has an antibacterial activity MIC value of 1 μg/mL against MRSA isolates expressing either G193D or G196S mutant FtsZ, retaining significant activity against the TXA707-resistant FtsZ mutant. It is being developed for use against Gram-negative bacteria. |
| M21091 | DS69910557 | DS69910557 is an oral parathyroid hormone (PTH) type 1 receptor (PTHR1) inhibitor that is being developed as a hypercalcemic compound. |
| M21090 | ITI-214 free base | ITI-214 free base is a potent inhibitor of CNS activity and an orally bioactive PDE1 inhibitor (Ki of 58 pM) with good selectivity for other PDE family members and a range of enzymes, receptors, transporters and ion channels. |
| M21066 | GCC5694A | GCC5694A is an oral SGLT2 inhibitor. SGLT2 inhibitors help people with diabetes control their blood sugar by preventing glucose reabsorption in the kidneys. |
| M21065 | BMS-820132 | BMS-820132 is an oral glucokinase (GK) partial activator for the study of diabetes mellitus. the AC50 is 29 nM. |
| M21064 | Bradanicline | Bradanicline (ATA-101; TC-5619) is a highly selective α7 nicotinic acetylcholine receptor (nAChR) agonist (EC50=17 nM for human α7 nAChR; Ki=1.4 nM). Bradanicline can be used to study cognitive impairment. |
| M21063 | LEO 134310 | LEO 134310 is a non-steroidal, selective glucocorticoid receptor (GR) agonist that is being studied in the first phase of plaque psoriasis.LEO 134310 has shown high affinity (EC50 of 14 nM) in GR binding assays.LEO 134310 can be used in dermatological conditions. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
